407 related articles for article (PubMed ID: 33406814)
21. Targeting ferroptosis contributes to ATPR-induced AML differentiation via ROS-autophagy-lysosomal pathway.
Du Y; Bao J; Zhang MJ; Li LL; Xu XL; Chen H; Feng YB; Peng XQ; Chen FH
Gene; 2020 Sep; 755():144889. PubMed ID: 32534056
[TBL] [Abstract][Full Text] [Related]
22. In vitro assessment of the sensitivity to APR-246 + azacitidine combination predicts response to this combination in myelodysplastic/acute myeloid leukaemia patients.
Maslah N; Diawara Y; Sebert M; Giraudier S; Fenaux P; Cassinat B
Br J Haematol; 2021 Aug; 194(4):e77-e79. PubMed ID: 34145569
[No Abstract] [Full Text] [Related]
23. A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death.
Ceder S; Eriksson SE; Cheteh EH; Dawar S; Corrales Benitez M; Bykov VJN; Fujihara KM; Grandin M; Li X; Ramm S; Behrenbruch C; Simpson KJ; Hollande F; Abrahmsen L; Clemons NJ; Wiman KG
EMBO Mol Med; 2021 Feb; 13(2):e10852. PubMed ID: 33314700
[TBL] [Abstract][Full Text] [Related]
24. To target the untargetable: elucidation of synergy of APR-246 and azacitidine in
Sallman DA
Haematologica; 2020 Jun; 105(6):1470-1472. PubMed ID: 32482751
[No Abstract] [Full Text] [Related]
25. Circadian clock protein Bmal1 accelerates acute myeloid leukemia by inhibiting ferroptosis through the EBF3/ALOX15 axis.
Wang D; Wang F; Zhang H; Chen P; Yang M
Cancer Sci; 2023 Aug; 114(8):3446-3460. PubMed ID: 37271497
[TBL] [Abstract][Full Text] [Related]
26. Human umbilical cord mesenchymal stem cells derived exosome shuttling mir-129-5p attenuates inflammatory bowel disease by inhibiting ferroptosis.
Wei Z; Hang S; Wiredu Ocansey DK; Zhang Z; Wang B; Zhang X; Mao F
J Nanobiotechnology; 2023 Jun; 21(1):188. PubMed ID: 37303049
[TBL] [Abstract][Full Text] [Related]
27. An all-in-one biomimetic iron-small interfering RNA nanoplatform induces ferroptosis for cancer therapy.
Huang S; Le H; Hong G; Chen G; Zhang F; Lu L; Zhang X; Qiu Y; Wang Z; Zhang Q; Ouyang G; Shen J
Acta Biomater; 2022 Aug; 148():244-257. PubMed ID: 35709941
[TBL] [Abstract][Full Text] [Related]
28. Lipid Peroxidation and Iron Metabolism: Two Corner Stones in the Homeostasis Control of Ferroptosis.
Rochette L; Dogon G; Rigal E; Zeller M; Cottin Y; Vergely C
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613888
[TBL] [Abstract][Full Text] [Related]
29. Ferroptosis: Role of lipid peroxidation, iron and ferritinophagy.
Latunde-Dada GO
Biochim Biophys Acta Gen Subj; 2017 Aug; 1861(8):1893-1900. PubMed ID: 28552631
[TBL] [Abstract][Full Text] [Related]
30. Edaravone, a free radical scavenger, protects against ferroptotic cell death in vitro.
Homma T; Kobayashi S; Sato H; Fujii J
Exp Cell Res; 2019 Nov; 384(1):111592. PubMed ID: 31479686
[TBL] [Abstract][Full Text] [Related]
31. APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations.
Hong Y; Ren T; Wang X; Liu X; Fei Y; Meng S; Han X; Sun C; Shen H; Li L; Qiu L; Qian Z; Zhou S; Zhang H; Wang X
Leukemia; 2022 Sep; 36(9):2269-2280. PubMed ID: 35835991
[TBL] [Abstract][Full Text] [Related]
32. Role of ferroptosis in the pathogenesis and as a therapeutic target of inflammatory bowel disease (Review).
Ocansey DKW; Yuan J; Wei Z; Mao F; Zhang Z
Int J Mol Med; 2023 Jun; 51(6):. PubMed ID: 37203397
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of Ferroptosis and Relations With Regulated Cell Death: A Review.
Lei P; Bai T; Sun Y
Front Physiol; 2019; 10():139. PubMed ID: 30863316
[TBL] [Abstract][Full Text] [Related]
34. Programmed Cell-Death by Ferroptosis: Antioxidants as Mitigators.
Kajarabille N; Latunde-Dada GO
Int J Mol Sci; 2019 Oct; 20(19):. PubMed ID: 31597407
[TBL] [Abstract][Full Text] [Related]
35. Ferroptosis in life: To be or not to be.
Xu L; Liu Y; Chen X; Zhong H; Wang Y
Biomed Pharmacother; 2023 Mar; 159():114241. PubMed ID: 36634587
[TBL] [Abstract][Full Text] [Related]
36. Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia.
Bruedigam C; Porter AH; Song A; Vroeg In de Wei G; Stoll T; Straube J; Cooper L; Cheng G; Kahl VFS; Sobinoff AP; Ling VY; Jebaraj BMC; Janardhanan Y; Haldar R; Bray LJ; Bullinger L; Heidel FH; Kennedy GA; Hill MM; Pickett HA; Abdel-Wahab O; Hartel G; Lane SW
Nat Cancer; 2024 Jan; 5(1):47-65. PubMed ID: 37904045
[TBL] [Abstract][Full Text] [Related]
37. Over-Expressed GATA-1
Trombetti S; Iaccarino N; Riccio P; Sessa R; Catapano R; Salvatore M; Luka S; de Nicola S; Izzo P; Roperto S; Maddalena P; Randazzo A; Grosso M
Antioxidants (Basel); 2023 Feb; 12(3):. PubMed ID: 36978786
[TBL] [Abstract][Full Text] [Related]
38. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.
Lehmann S; Bykov VJ; Ali D; Andrén O; Cherif H; Tidefelt U; Uggla B; Yachnin J; Juliusson G; Moshfegh A; Paul C; Wiman KG; Andersson PO
J Clin Oncol; 2012 Oct; 30(29):3633-9. PubMed ID: 22965953
[TBL] [Abstract][Full Text] [Related]
39. Targeting NRF2 uncovered an intrinsic susceptibility of acute myeloid leukemia cells to ferroptosis.
Liu X; Zhong S; Qiu K; Chen X; Wu W; Zheng J; Liu Y; Wu H; Fan S; Nie D; Wang X; Yu Z; Liao Z; Zhong M; Li Y; Zeng C
Exp Hematol Oncol; 2023 May; 12(1):47. PubMed ID: 37198609
[TBL] [Abstract][Full Text] [Related]
40. Targeting GPX4 in human cancer: Implications of ferroptosis induction for tackling cancer resilience.
Lee J; Roh JL
Cancer Lett; 2023 Apr; 559():216119. PubMed ID: 36893895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
